Igeahub.com - Top Pharma News - Luca Dezzani

Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At igeahub.com, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The … Continue reading Pharma 2016: One Year in Review

Advertisements
Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – November 2016

New Research Details Published by Merck Scientists About the Early Development of Verubecestat November 2, 2016 Merck has announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat. It is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is used … Continue reading Top Pharma News – November 2016

BMS logo

Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Safety and Efficacy in Previously Treated Patients with Advanced Form of Bladder Cancer

November 12, 2016 Bristol-Myers Squibb Company has announced positive results from the Phase 1/2 open-label CheckMate-032 trial that investigates two combination schedules of Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with locally advanced or metastatic urothelial carcinoma (mUC) previously treated with platinum-based therapy. These data were presented during the Oral Late-breaking Abstract Session II, at the 31st Annual Meeting and Associated … Continue reading Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Safety and Efficacy in Previously Treated Patients with Advanced Form of Bladder Cancer

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Fall 2016

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen … Continue reading Pharma Oncology | Top News – Fall 2016

abbvie-bristol

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen of Bristol-Myers Squibb as a treatment for relapsed extensive-stage small cell lung cancer (SCLC). “We believe the combination … Continue reading AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – June 2016

Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer June 6, 2016 Astellas Pharma Inc. and Seattle Genetics, Inc. (NASDAQ: SGEN) have presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting that was held in June 3-7, 2016 in Chicago, IL.   … Continue reading Top Pharma News – June 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Spring 2016

GSK Returns to War against Cancer April 3, 2016 It looked like the UK pharmaceuticals group GlaxoSmithKline (GSK) was declaring surrender in the war on cancer when the company agreed to sell its oncology drugs for $16 billion to Novartis in 2014. However, after two years, GSK returns to this war on cancer again.   … Continue reading Pharma Oncology | Top News – Spring 2016

BMS logo

New Data on Opdivo (nivolumab) from Bristol-Myers Squibb Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

June 10, 2016 Bristol-Myers Squibb Company has announced results from CheckMate -205, a multi-cohort, single-arm, non-comparative, Phase 2 registrational trial evaluating Opdivo (nivolumab) in classical Hodgkin lymphoma (cHL) patients. The results included patients who had relapsed or progressed after post-transplantation brentuximab vedotin and autologous hematopoietic stem cell transplantation (auto-HSCT). The primary endpoint of objective response rate (ORR) per … Continue reading New Data on Opdivo (nivolumab) from Bristol-Myers Squibb Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – May 2016

Taltz® (ixekizumab) Now Available in the U.S. for Treating Plaque Psoriasis May 2, 2016 Eli Lilly and Company has announced that Taltz® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available in the United States by prescription order through a contracted network of specialty pharmacies. Patient support programs are also offered by Lilly … Continue reading Top Pharma News – May 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – April 2016

AbbVie Agrees to Buy Stemcentrx April 28, 2016 Pharmaceutical company AbbVie Inc. has agreed to acquire Stemcentrx Inc., a cancer-drug developer, for $5.8 billion. This is part of AbbVie’s continuing aggressive push for building an oncology business. Keytruda Shows Promise in Patients with Merkel Cell Carcinoma, A Rare Form of Skin Cancer April 19, 2016 … Continue reading Top Pharma News – April 2016